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Abstract
Background: Breast cancer, as the most frequent cancer diagnosed in women worldwide, is affected by different regulatory mech-
anisms and cellular processes such as microRNAs (miRNAs) and autophagy, which influence tumor cell progression. MiRNAs play
a crucial role in cancer progression. Aberrant miRNA expression has been described in various human cancers. Growing evidence
proposes that miRNAs have a considerable role in tumor development and may constitute robust biomarkers for cancer diagnosis
and prognosis.
Objectives: The aim of this study was to evaluate miRNA-638 (miR-638) expression level in breast cancer patients and its bioinfor-
matics analysis.
Methods: In this case-control study, miR-638 expression was examined in fresh breast tissues of 47 patients with breast cancer using
real time polymerase chain reaction (PCR). Then the role of miR-638 in various signaling pathways was studied using Target Scan,
the MicroRNA-Target Interactions (miRTarBase) database, miRWalk2.0 and the database for annotation, visualization and integrated
discovery (DAVID).
Results: The miR-638 expression level showed a significant decrease in breast cancer patients. Also, this miRNA might be involved
in apoptosis, angiogenesis, and autophagy.
Conclusions: According to the results, miR-638 can be used as a potential prognostic biomarker for cancer growth, and its low
expression is thought to increase cancer progression by disrupting cell death and autophagy, which are considered as important
pathways in breast cancer.
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1. Background
Breast cancer is the most commonly diagnosed malig-
nancy in women worldwide and is considered to be re-
sponsible for 30% of the total new cancer cases and 14% of
overall cancer mortality (1). In spite of huge efforts, the
definite molecular mechanisms of breast cancer tumori-
genesis have largely remained unknown. Therefore, dis-
covering the mechanisms involved in breast cancer and
unraveling the factors that contribute to the formation of
such mechanisms, will help scientists to define new di-
agnostic and prognostic biomarkers for this cancer (2, 3).
On the other side, it has been shown that three molec-
ular pathways, including cell death, autophagy, and an-
giogenesis are dysregulated in breast cancer. Biomarkers
used for early detection of cancer have the potency to re-
duce the burden of cancer in the population (4). MicroR-
NAs (miRNAs) are one of the most important classes of bi-
ological molecules and their role in the regulation of var-
ious molecular mechanisms has been proven by many re-
searches (5). MiRNA expression profiles are dysregulated
in different types of cancers. Some studies have suggested
that miRNA expression levels correlate with prognosis of
breast cancer (6-8); miR-638 is one of these miRNAs, which
is located on chromosome 19p13.2 and downstream of ILF3
and QTRT1 genes (9, 10).
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Altered expression of miR-638 has been identified in
several different types of human tumors. For example, its
expression was dramatically reduced in the human gas-
tric tumor (11), basal cell carcinoma (12), breast cancer (13),
non-small cell lung cancer (14), colorectal tumor (15), and
chronic lymphocytic leukemia (16); therefore it might have
a potential suppressing role in these cancers. Moreover, re-
searchers found that miR-638 has a role in the regulation
of the metastasis, autophagy and apoptosis processes in
melanoma (17). A recent study demonstrated that the ex-
pression level of miR-638 was decreased in tissue samples
of liver cancer compared with normal liver tissues, leading
to angiogenesis promotion (18).
2. Objectives
The aim of the current study was (a) to use bioinfor-
matics resources to prioritize susceptible miRNAs impli-
cated in breast cancer, (b) to evaluate the expression level
of prone miRNAs in clinical samples, (c) to use bioinfor-
matics analysis of candidate miRNAs by referring to differ-
ent databases in order to detect potential signaling path-
ways that they are involved in, and (d) to investigate the ex-
pression analysis of miR-638 in patients with breast cancer.
3. Methods
3.1. RNA Prediction
At first, the Target Scan (TargetScanHuman7.1) and
Diana Tools (Diana Tools MicroT-CDS) were used to pre-
dict miR-638 target genes which have the potential
binding sites on their three prime untranslated re-
gion, according to the Software for Statistical Folding
of Nucleic Acids and Studies of Regulatory RNAs (SFold
database) (http://sfold.wadsworth.org). Then, the Hu-
man Protein Atlas (https://www.proteinatlas.org/) and the
Human microRNA Disease Database v3.0 (HMDD v3.0)
(http://www.cuilab.cn/hmdd) web-based programs were
used to determine mRNA and miRNA expression levels.
3.2. Samples Collection
This study was conducted on a total of 47 breast cancer
samples and matched-pair adjacent non-cancerous tissues
from newly diagnosed patients with breast cancer at the
Imam Khomeini Hospital of Tehran University of Medical
Sciences between 2015 and 2018. All the clinical samples
were collected from Iran National Tumor Bank (The Can-
cer Institute, Imam Khomeini Hospital, Tehran, Iran). All
the contributors were asked to read and sign an informed
consent prior to tumor sample collection and following
molecular analysis for the present study.
Specimens were removed during a surgical procedure,
and a pathologist distinguished tumor tissue from adja-
cent healthy tissue, as a normal sample. Then the spec-
imens were immediately frozen in liquid nitrogen, and
stored at -80ºC until RNA extraction. All tests were carried
out in conformity with relevant guidelines.
3.3. RNA Isolation
Total RNA was extracted from the samples using
TRIZOL-Reagent RNA isolation agent (Invitrogen Carlsbad,
CA). RNA extraction from tissue samples was performed ac-
cording to the manufacturer’s protocol. The quantity of
RNA was measured using Nano Drop spectrophotometer
ND-2000 (Thermo Scientific), and RNA quality was assessed
by running the RNA on 1.5% agarose gel electrophoresis.
3.4. cDNA Synthesis and qPCR
Complementary DNA (cDNA) synthesis was performed
on 1µg of extracted total RNA, using a TruScript First Strand
cDNA Synthesis Kit (Norgen Canada) for 5srRNA (5S riboso-
mal RNA; as endogenous control of miRNA) according to
manufacturer’s protocol. Quantitative polymerase chain
reaction (qPCR) was done in triplicate, for each sample, on
the Rotor-Gene Q instrument (Qiagen) using 2X Real-Time
PCR Master Mix (Norgen, Canada). 2X SYBR Green master
mix (5µL), 1µL of cDNA samples, 0.5µL of each forward and
reverse primers (2 pmol) and 3 µL of nuclease-free water
(Norgen, Canada) were mingled in Strip Tubes and Caps,
0.1 mL (Qiagen) to perform PCR in a 10 µL reaction vol-
ume. The PCR amplifications were performed according to
the following program for the thermal cycler instrument:
an initial denaturing step for 2 min at 95ºC, followed by
40 cycles of denaturation at 95ºC and combined anneal-
ing/extension at 60ºC for 20 sec and 30 sec, respectively.
5srRNA was used as the reference for expression alterations
comparison and the fold change in the expression of each
target mRNA, relative to 5srRNA, was evaluated based on
the 2-∆∆ct comparative expression Livak method (19).
The quantitative assay of mature miRNAs was carried
out using the miR-Q method as described by Sharbati-
Tehrani et al. (20) with sequence-specific oligonucleotide
primers. Table 1 describes the utilized oligonucleotides.
Briefly, 3µL of miRNA cDNA products was added to master
mix containing 1µL MP primers (Fw + Rev), 1µL short-miR-x
and 5 µL of SYBR, in total volume of 10 µL. The qPCRs were
executed in triplicate according to the standard program
on Rotor-Gene Q instrument (QIAGEN, Germany). Thermal
cycler was programmed to run according to the following
conditions: 95ºC for 2 min followed by 40 cycles of dena-
turing at 95ºC for 15s and combined annealing-extension
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for 30 s at 60ºC. Moreover, a non-template control (NTC) re-
action was employed for each primer set to guarantee the
reaction specificity.
3.5. Bioinformatics Analysis
The study was carried out through bioinformatics
methods and by using miRWalk, MicroRNA-Target Inter-
actions (miRTarBase) database, and the database for an-
notation, visualization and integrated discovery (DAVID).
MiRWalk2.0 database, that predicts miRNA-mRNA interac-
tions, provided a list of more than a thousand genes. By
using miRTarBase, prone genes were evaluated and com-
pared with the previous list.
Then, by using the UniGene database, the expression
of target mRNAs was analyzed in mammary gland cells
to determine which mRNA is expressed in the mammary
gland. Ultimately, to carry out signaling pathways en-
richment analysis, miR-638 targetome expressed in mam-
mary glands was included in the DAVID database 6.8.
This database yields results obtained from pathway anal-
yses performed by the Kyoto Encyclopedia of Genes and
Genomes (KEGG) database to detect the molecular net-
works and signaling pathways including the most miR-638
targetome.
3.6. Statistical Analysis
The data obtained from real-time PCR were analyzed
by using the∆∆CT method in SPSS software version 25.0
(Chicago, IL, USA). Normal distribution of data was exam-
ined by the Shapiro-Wilk test. All tests were carried out in
triplicate, and data were presented as mean [± standard er-
ror of measurement (SEM)]. Wilcoxon and Mann-Whitney
U tests were used for analysis with SPSS (version 25.0) and
GraphPad Prism (version 6.0) software. In all the tests, P
value < 0.05 indicated a significant difference.
4. Results
4.1. Characteristics of Collected Samples
The study consisted of 47 breast tumor specimens and
their paired non-cancerous samples. Information regard-
ing clinicopathological factors and demographic charac-
teristics such as age, tumor size, grade, stage, site of pri-
mary tumor, necrosis presence, vascular invasion, perineu-
ral invasion, family history, lymphatic invasion, and duc-
tal carcinoma in situ (DCIS) have been described in Table 2.
From the point of the tumor size, stage and grade, the ma-
jority of the tumors were less than 5 cm, stage 2 and grade
2, respectively. Most of the patients didn’t have a positive
family history; however, their tumors had a vascular and
lymphatic invasion.
4.2. Expression of miR-638 in Breast Cancer Samples
Data showed that the expression of miR-638 in tumoral
tissues decreased significantly, in comparison with their
paired normal adjacent tissues (2.13 ± 0.82). Figure 1A
shows the relative miR-638 expression in patients and the
control group. Correlation analysis was conducted to find
possible relations between the expression of miR-638 and
the clinicopathological characteristics of the patients, in-
cluding age, site of primary tumor, tumor size, grade,
stage, and HER2 status (Table 3). A significant low expres-
sion of miR-638 was observed in the tumoral samples, in
comparison with adjacent non-tumoral samples. Interest-
ingly, with the progression of disease from stage 2 to stage
3, the expression level of miR-638 increased, which impli-
cated cancer growth. As shown below, the mean expression
of miR-638 in the stage II group was 0.67 ± 0.12, while in
low tumor stage cluster was 1.14 ± 0.20 (P = 0.041; Figure
1B). Nevertheless, no significant association was observed
in respect to age, site of primary tumor, tumor size, grade,
and HER2 (Table 3).
4.3. Signaling Pathway Enrichment Analysis of miR-638 Targe-
tome
Molecular signaling pathway enrichment analysis was
conducted to study the potential roles of miR-638 in the
tumorigenesis and progression of breast cancer. All of
the 1152 predicted mRNAs and 53 validated mRNAs which
were obtained from miRWalk and miRTarBase respectively
were targeted by miR-638. All the validated targets drawn
from the miRTarBase database were confirmed by persua-
sive tests, such as western blot, quantitative real-time PCR,
and reporter assay. Thirty-eight out of the 53 validated mR-
NAs (71%) were also observed in the list of predicted mR-
NAs, confirmed by at least five prediction databases, which
demonstrated that the threshold of five databases is reli-
able to select predicted miR-638 targets. The targets’ ex-
pression profiles in the UniGene database revealed that
only 38 out of the validated mRNA targets and 1018 out
of the predicted ones were expressed in mammary gland
cells. These targets were selected as miR-638 targetome for
additional molecular enrichment analysis. Next, the se-
lected miR-638 targetome was entered into the DAVID func-
tional annotation to investigate whether the association
of the entered genes with signaling pathways and biolog-
ical terms was statistically significant. Findings from the
miRWalk2.0 database and signaling pathways, which have
been obtained from DAVID, indicated that the change in
the expression level of miR-638 could deviate the cell from
its original pathway by affecting cells’ target genes during
apoptosis, autophagy, and angiogenesis (Figure 2). Table 4
displays the pathways obtained from the DAVID database
and their P value.
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Table 1. Designed Oligonucleotides for the Target Sequences
Name Sequence (5’ to 3’)
5S rRNA- Fw GCCCGATCTCGTCTGATCT
5S rRNA-Rev AGCCTACAGCACCCGGTATT
RT6-miR-638 TGTCAGGCA ACCGTATTCACCGTGAGTAGGCCG
Short-miR-638 CGTCAGATGTCCGAGTAGAGGGGGAACGGCAGGGATCGCGGGCGGGTGG
MP-Fw TGTCAGGCAACCGTATTCACC
MP-Rev CGTCAGATGTCCGAGTAGAGG
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Figure 1. Expression of miR-638 was evaluated by RT-qPCR in breast cancer tissues. A) According to the statistical analysis, miR-638 expression decreased in breast cancer
tissue samples, compared with adjacent noncancerous tissue samples (Wilcoxon test). B) Differential expression of miR-638 in stage II and III of breast cancer patients. Values
represent means and error bars represent the SEM (P < 0.0001 and P < 0.05 respectively).
5. Discussion
Recent studies have indicated that miRNAs play a cru-
cial regulatory role in many cancers (21). Therefore, it can
be deduced that miRNAs may have a promising and promi-
nent prognostic and diagnostic value in different cancers,
such as breast cancer (22). The data obtained from the
present study showed that the expression level of miR-638
was down-regulated in breast cancer tissues compared to
matched-tumor-adjacent tissues. Furthermore, reduced
miR-638 expression was correlated with clinicopathologi-
cal characteristics of breast cancer patients, including ad-
vanced stage. The expression level of miR-638 was higher in
stage 3, compared with stage 2 (Figure 1B). Since the down-
regulation of miR-638 occurred in lower stages, but not in
higher stages, it may indicate that the need for more angio-
genesis is the cause of the up-regulation of miR-638. From
obtained results and bioinformatics data, it can be inferred
that the low expression of miR-638 is associated with a de-
crease in apoptosis. Thus, it can be understood that the up-
regulation of miR-638 in patients with breast cancer, is as-
sociated with poor prognosis; for this reason, this miRNA
can be used as a potential prognostic biomarker.
Bioinformatics analysis revealed that dysregulation of
miR-638 had a role in angiogenesis and the inhibition of
autophagy. miR-638 has many target genes including ATG-
5, ATG-2B, VEGF, TP53, and TRAF (23, 24). Apoptosis is a normal
cellular process which leads to controlling the growth and
development rate. Excessive activity of apoptosis causes
diseases such as Alzheimer’s and Parkinson and if apopto-
sis rate is too little, it can lead to cancer (25). The genes in-
volved in apoptosis have the potential to be regulated by
microRNAs. In the apoptosis pathway, which was induced
by miR-638, a change in the P53 protein was observed. TP53
is a tumor suppressor gene and mutations in this gene
have been indicated in most of the human cancers. This
gene plays an important role in suppressing the tumor,
stopping the cell cycle, inducing apoptosis, and inhibiting
angiogenesis (26).
The proteins that play a role in apoptosis pathway are
divided into 2 groups: (i) anti-apoptotic proteins, which in-
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Figure 2. Overview of signaling pathways and miR-638 target genes obtained from DAVID data base, marked with a star sign. Image taken from David’s database at
https://david.ncifcrf.gov.
Figure 3. Genes involved in delaying cell death. The target genes of miR-638 are
marked with a star (This image is captured from image 4).
clude Bcl-2 and TRAFs, and (ii) pro-apoptotic members that
include BAX, and BAK. These proteins, by binding to the
outer membrane of mitochondria and inhibition of pro-
apoptotic family members, maintain the mitochondrial
membrane and inhibit apoptosis (27) (Figure 3).
Since tumor cells have fast and uncontrolled growth
in comparison to normal cells, some of them that are far
from blood vessels encounter with hypoxia or lack of oxy-
gen. Therefore, angiogenesis begins inside and around the
tumor to provide the oxygen needed for the cancer cells
(28). VEGF is one of the most significant proteins in the an-
giogenesis process, and miR-638 alters its expression (18).
Figure 4 shows the genes induced by miR-638 in the angio-
genesis pathway.
Bioinformatics analyses indicated that miR-638 exerts
its effect through affecting ATG-5 and ATG-2B proteins,
which play a role in cellular autophagy. MiR-638 leads to
autophagy inhibition by targeting the genes in the elonga-
tion phase. Further studies are needed to illustrate the ef-
fects of reducing the expression of miR-638 in autophagy.
The findings of this study indicate how miR-638 affects in-
tracellular pathways, including autophagy and angiogen-
esis, which lead to the progression of breast cancer.
Our results and bioinformatics analysis showed that
downregulation of miR-638 may be associated with a good
prognosis in breast cancer, because with decreases in miR-
638 expression level, we observed the overexpression of
ATG-5 and TP53 genes, which are involved in autophagy and
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Table 2. General Demographic Data of Study Participants
Variable Value
Tumor size (%)
< 3 cm 17 (36.2)
≥ 3 to < 5 cm 17 (36.2)
≥ 5cm 13 (27.7)
Grade (%)
I 4 (8.5)
II 22 (46.8)
III 21 (44.7)
Stage (%)
II 32 (68.1)
III 15 (31.9)
Site of primary tumor
Right Breast 25 (53.2)
Left Breast 18 (38.3)
Bilateral 4 (8.5)
Necrosis presence
Yes 21 (44.7)
No 26 (55.3)
Vascular invasion
Yes 30 (63.8)
No 17 (36.2)
Perineural invasion
Yes 15 (31.9)
No 32 (68.1)
Family history
Yes 15 (31.9)
No 32 (68.1)
Lymphatic invasion
Yes 27 (57.1)
No 20 (42.6)
DCIS
Present 36 (76.6)
Absent 11 (23.4)
apoptosis, respectively.
In line with our study, Zhang et al. observed that miR-
638 expression was reduced in colorectal cancer tissues,
in comparison to their adjacent normal tissues (15). On
the other hand, the mean expression level of miR-638 was
significantly up-regulated in prostate and kidney cancers
(29). Taken together, it can be suggested that miR-638 may
have a potential prognostic role in breast cancer patients.
Table 3. Association of miR-638 Expression Levels and Clinicopathological Charac-
teristics of Cancerous Breast Samples
Feature
miR-638
Mean± SEM P
Age
< 54 0.72± 0.15 0.196
≥ 54 0.93± 0.16
Site of primary tumor
Left 0.98± 0.18 0.277
Right 0.69± 0.14
Bilateral 0.98± 0.48
Tumor size
< 3 cm 0.83± 0.19 0.928
≥ 3 to < 5 cm 0.78± 0.17
≥ 5cm 0.19± 0.22
Grade
I 1.01± 0.48 0.655
II 0.73± 0.16
III 0.89± 0.15
Stage
II 0.67± 0.12 0.041
III 1.14± 0.20
HER2
Positive 1.18± 0.21 0.167
Negative 0.74± 0.15
Table 4. The Signaling Paths Obtained from the DAVID Database and Their P-Value
Derived from DAVID
KEGG Pathway P Value
MicroRNA in cancer 4.3E-6
PI3K-Akt signaling pathway 5.7E-4
Notch signaling pathway 7.7E-4
Pathway in cancer 2.1E-3
AMPk signaling pathway 2.2E-3
5.1. Conclusions
The results of the present study indicate a significant
expression pattern difference of miR-638 in breast tumor
specimens and their paired non-cancerous samples. Our
findings showed that miR-638 was down-regulated in can-
cerous samples and was associated with higher stages.
We conducted bioinformatics research to reach the target
genes of miR-638, which can have the greatest impact on
the pathways leading to cancer progression, and the pos-
sibility of using this miRNA in cancer prognosis. These
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Figure 4. The genes induced by miR-638 in the angiogenesis pathway. The target
genes of miR-638 are marked with a star.
results demonstrate that miR-638 might serve as a poten-
tial prognostic biomarker; however, more investigation is
needed.
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